CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Mye...
22 Junio 2020 - 8:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that its
partner Bristol Myers Squibb presented preclinical data from
BMS-986249 and BMS-986288, anti-CTLA-4 Probody therapeutics
generated with CytomX’s novel Probody® technology platform. The
electronic poster #4551 titled “Preclinical characterization of
novel anti-CTLA-4 prodrug antibodies with an enhanced therapeutic
index” was presented as part of the Therapeutic Antibodies 3
Session at the American Association of Cancer Research’s (AACR)
2020 Virtual Annual Meeting II.
BMS-986249 is a Probody version of the anti-CTLA-4 antibody
ipilimumab (Yervoy®). In February 2020, Bristol Myers Squibb
treated the first patient in a Part 2a randomized cohort expansion
in an ongoing Phase 1/2a trial of BMS-986249 in combination with
Opdivo® (nivolumab) in patients with metastatic melanoma.
Additional information is available at ClinicalTrials.gov using the
Identifier NCT03369223.
BMS-986288 is a Probody of a nonfucosylated version of
ipilimumab (anti-CTLA-4 NF). In September 2019, Bristol Myers
Squibb initiated the dose escalation phase of a Phase 1/2a clinical
trial of BMS-986288 administered as monotherapy and in combination
with nivolumab in patients with selected advanced solid tumors.
Additional information is available at ClinicalTrials.gov using the
Identifier NCT03994601.
These Probody programs, designed to optimize the therapeutic
index of CTLA-4-directed therapy, arose from the companies’ 2014
worldwide oncology license and collaboration agreement.
“This important work within our Bristol Myers Squibb alliance is
aimed at broadening the utility of this foundational
immunotherapeutic approach to the treatment of cancer,”
said Sean McCarthy D.Phil., president, chief executive officer
and chairman of CytomX Therapeutics. “We look forward to
seeing the full potential of these programs as they continue to
advance in the clinic.”
About CytomX Therapeutics CytomX is a
clinical-stage, oncology-focused biopharmaceutical company with a
vision of transforming lives with safer, more effective therapies.
We are developing a novel class of investigational antibody
therapeutics, based on our Probody® technology platform, for
the treatment of cancer. Probody therapeutics are designed to
remain inactive until they are activated by proteases in the tumor
microenvironment. As a result, Probody therapeutics are intended to
bind selectively to tumors and decrease binding to healthy tissue,
to minimize toxicity and potentially create safer, more effective
therapies. As leaders in the field, our innovative technology is
designed to turn previously undruggable targets into druggable
targets and to enable more effective combination therapies. CytomX
and its partners, comprised of leading biotechnology and
pharmaceutical companies, have developed a robust pipeline of
potential first-in-class therapeutic candidates against novel,
difficult to drug targets and potential best-in-class
immunotherapeutic candidates against clinically validated targets.
The CytomX clinical stage pipeline includes first-in-class product
candidates against previously undruggable targets, including a
CD166-targeting Probody drug conjugate wholly owned by CytomX
(CX-2009) and a CD71-targeting Probody drug conjugate partnered
with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that
are considered to be inaccessible to conventional antibody drug
conjugates due to their presence on many healthy tissues. The
CytomX clinical stage pipeline also includes cancer
immunotherapeutic candidates against validated targets such as our
wholly owned anti-PD-L1 Probody therapeutic, CX-072, and the
CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288,
partnered with Bristol Myers Squibb. CytomX has strategic drug
discovery and development collaborations with AbbVie, Amgen,
Astellas and Bristol Myers Squibb. For additional information
about CytomX Therapeutics,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements, including those relating to
the potential benefits, safety and efficacy or progress of CytomX’s
or any of its collaborative partners’ product candidates, the
potential benefits or applications of CytomX’s Probody platform
technology, and CytomX’s ability to develop and advance product
candidates into and successfully complete clinical trials,
including the ongoing and planned clinical trials of CX-2009 and
CX-2029. Risks and uncertainties that contribute to the uncertain
nature of the forward-looking statements include: the unproven
nature of CytomX’s novel Probody Platform technology; CytomX’s
clinical trial product candidates are in the initial stages of
clinical development and its other product candidates are currently
in preclinical development, and the process by which preclinical
and clinical development could potentially lead to an approved
product is long and subject to significant risks and uncertainties,
including the risk that the COVID-19 worldwide pandemic may
continue to negatively impact the business, research and clinical
operations of CytomX or its partners, including the development of
preclinical drug candidates due to delays in and disruption of
research activities and the development of clinical drug candidates
due to delays in or disruption of clinical trials, including
impacts on the enrollment of patients in clinical trials or other
clinical trial disruptions; the possibility that the results of
early clinical trials may not be predictive of future results; the
possibility that CytomX’s clinical trials will not be successful;
the possibility that current pre-clinical research may not result
in additional product candidates; CytomX’s dependence on the
success of CX-2009, CX-2029, BMS-986249, BMS-986288, and CX-072;
CytomX’s reliance on third parties for the manufacture of the
company’s product candidates; and possible regulatory developments
in the United States and foreign countries.
Additional applicable risks and uncertainties include those
relating to our preclinical research and development, clinical
development, and other risks identified under the heading "Risk
Factors" included in CytomX’s Quarterly Report on Form 10-Q filed
with the SEC on May 7, 2020. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise. Probody is a U.S. registered
trademark of CytomX Therapeutics, Inc. Yervoy and Opdivo are
registered trademarks of Bristol Myers
Squibb.
Investor and Media Contact: Christopher Keenan VP, Investor
Relations and Corporate Communications
ckeenan@cytomx.com 650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024